glp-1 receptor agonist and dpp-4 inhibitor combination not recommended analogues inhibitors in type 2 diabetes therapy: from structural biology to clinics dpp-4 inhibitor and glp-1 receptor

Defending ADA's A1c target

Acting proactively places a clinic in a materially better position than responding to enforcement action after the fact

With more companies competing for this indication, the hope is to see a reduction in price for GLP-1 products with increased competition

Supervision matters: these are prescription level compounds, so a licensed provider, real sourcing, and follow up separate a safe plan from a risky one

The COVID-19 global pandemic, or any future public health crisis, and the ensuing policies enacted by governments and central banks have caused and may continue to cause significant volatility and uncertainty in global financial markets, negatively impacting global growth prospects

From looking at the reported data in the paper, BPC-157 worked no better than the high dose platelet-rich plasma (PRP) that our lab research group tested in another study (3)